Back to top
more

UnitedHealth Group (UNH)

(Delayed Data from NYSE)

$237.77 USD

237.77
39,914,914

-11.79 (-4.72%)

Updated Aug 1, 2025 03:59 PM ET

After-Market: $237.50 -0.27 (-0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 1% (245 out of 246)

Industry: Medical - HMOs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

UnitedHealth Group, Inc. is the largest health care services company in the world, serving over 50 million individuals in the United States as of 2019 and over 5 million internationally. The company provides a wide range of health care products and services, such as health maintenance organizations (HMOs), point of service plans (POS), preferred provider organizations (PPOs), and managed fee-for-service programs. UnitedHealth has the largest and most diverse membership base within the managed-care organization market, which gives it significant competitive advantages. It also has built its prescription drug business through OptumRx division, with the acquisition of Catamaran in 2015.

Zacks Equity Research

Stock Market News for Jul 30, 2025

by Zacks Equity Research

Wall Street closed lower on Tuesday, pulled down by industrial and discretionary stocks.

Zacks Equity Research

UnitedHealth Q2 Earnings Miss Estimates on Increasing Medical Costs

by Zacks Equity Research

UNH misses Q2 earnings estimates as surging medical costs slash EPS 40%, despite revenue growth and Optum Rx strength.

Zacks Equity Research

Trade Deficit Comes in Lower Than Expected

by Zacks Equity Research

Trade Deficit Comes in Lower Than Expected.

Mark Vickery headshot

Pre-Markets Up Again on Big News Morning

by Mark Vickery

From a vast array of earnings reports to key economic prints to a massive railway merger likely to pass its government board, it's been a busy morning.

Zacks Equity Research

Here's What Key Metrics Tell Us About UnitedHealth (UNH) Q2 Earnings

by Zacks Equity Research

Although the revenue and EPS for UnitedHealth (UNH) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

UnitedHealth Group (UNH) Q2 Earnings Lag Estimates

by Zacks Equity Research

UnitedHealth (UNH) delivered earnings and revenue surprises of -15.70% and +0.06%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Mark Vickery headshot

S&P 500 & Nasdaq Notch New All-Time Closing Highs

by Mark Vickery

Markets lost a bit of steam mid-session this Monday, but a late surge into the close brought the S&P 500 and the Nasdaq indexes to new record closing highs.

Zacks Equity Research

Can Optum Support UnitedHealth's Profit Amid Industry Headwinds?

by Zacks Equity Research

UNH leans on Optum's diversified growth and value-based care to counter insurance sector margin pressure in Q2.

Zacks Equity Research

Is It Worth Investing in UnitedHealth (UNH) Based on Wall Street's Bullish Views?

by Zacks Equity Research

According to the average brokerage recommendation (ABR), one should invest in UnitedHealth (UNH). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Urmimala Biswas headshot

CVS or UnitedHealth: Which Stock Is a Better Buy Ahead of Q2 Earnings?

by Urmimala Biswas

CVS shows resilience with stable insurance margins and capital discipline, while UNH faces cost headwinds and a sharp earnings cut.

Kaibalya Pravo Dey headshot

UnitedHealthcare Pressure Builds: Trouble Ahead for UNH's Q2 Earnings?

by Kaibalya Pravo Dey

UNH braces for a steep Q2 profit drop as soaring medical costs and DOJ scrutiny shake investor confidence.

Zacks Equity Research

Medical Expenses Erode Centene's Bottom Line in Rare Q2 Earnings Miss

by Zacks Equity Research

CNC reports rare Q2 loss amid surging medical costs, lower investment and other income despite strong revenue growth.

Zacks Equity Research

Centene (CNC) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Centene (CNC) delivered earnings and revenue surprises of -123.53% and +10.93%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

UnitedHealth Group (UNH) Stock Sinks As Market Gains: Here's Why

by Zacks Equity Research

In the closing of the recent trading day, UnitedHealth Group (UNH) stood at $278.58, denoting a -4.76% move from the preceding trading day.

Kaibalya Pravo Dey headshot

UnitedHealth on Thin Ice Before Q2 Earnings: Should Investors Exit?

by Kaibalya Pravo Dey

UNH braces for a 27% earnings drop in Q2 as soaring medical costs, margin pressure and investor jitters weigh on performance.

Zacks Equity Research

Pre-Markets Mixed Despite Strong Earnings Results

by Zacks Equity Research

Pre-Markets Mixed Despite Strong Earnings Results.

Mark Vickery headshot

Morning Headlines Defy Expectations, but Pre-Markets Sell

by Mark Vickery

Only the tech-heavy (AI-trade-heavy) Nasdaq is in the green at this hour.

Zacks Equity Research

Wall Street's Insights Into Key Metrics Ahead of UnitedHealth (UNH) Q2 Earnings

by Zacks Equity Research

Evaluate the expected performance of UnitedHealth (UNH) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Zacks Equity Research

UnitedHealth Group Incorporated (UNH) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Zacks.com users have recently been watching UnitedHealth (UNH) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Urmimala Biswas headshot

CVS Q2 Estimates Dip: Is the Stock Still a Buy Ahead of Q2 Earnings?

by Urmimala Biswas

Earnings estimates for CVS dip ahead of Q2 results, but turnaround efforts in Aetna and PBM strength may offset pressure.

Zacks Equity Research

Humana (HUM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Humana (HUM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Moumi Mondal headshot

What's Shaping CVS' Health Care Benefits Arm for the Rest of 2025?

by Moumi Mondal

CVS Health's Health Care Benefits arm posts solid Medicare gains and prepares for an ACA exit with a $448M reserve.

Zacks Equity Research

Analysts Estimate UnitedHealth Group (UNH) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

UnitedHealth (UNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

UnitedHealth Group (UNH) Sees a More Significant Dip Than Broader Market: Some Facts to Know

by Zacks Equity Research

UnitedHealth Group (UNH) closed the most recent trading day at $282.65, moving 1.88% from the previous trading session.

Moumi Mondal headshot

CVS Health's Caremark to Lead CalPERS' PBM Vision: What's at Stake?

by Moumi Mondal

CVS wins a major CalPERS deal as Caremark replaces OptumRx, backed by $250M in performance guarantees and drug cost controls.